Coronavirus Scientific Advisory Board (Turkey)

Anavex Life Sciences Reports Fiscal 2023 First Quarter Financial Results

Retrieved on: 
Tuesday, February 7, 2023
Disease, EDGAR, Research, Clinical trial, Neurodegeneration, Rett syndrome, CNS, Cognition, Conference call, Congress, Therapy, ADAS-Cog, Webcast, Publication, Conference, Coronavirus Scientific Advisory Board (Turkey), Central nervous system, Drug development, Patient, Society, SIGMAR1, Dementia, Precision medicine, Office of the National Coordinator for Health Information Technology, Nature, Data, Doctor of Philosophy, Broadcasting, Pharmaceutical industry, Video game, MD

NEW YORK, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today reported financial results for its fiscal quarter ended December 31, 2022.

Key Points: 
  • Company expects to announce topline results from this study in the second half of 2023.
  • On January 12th, 2023, Anavex presented at the 41st Annual J.P. Morgan Healthcare Conference, in San Francisco, CA.
  • General and administrative expenses for the quarter of $3.3 million compared to $3.1 million for the comparable quarter of fiscal 2022.
  • Research and development expenses for the quarter of $12.1 million compared to $8.7 million for the comparable quarter of fiscal 2022.

Senior Leadership Changes at Idaho Milk Products

Retrieved on: 
Wednesday, January 25, 2023
Common white wave, Marketing, Global Accounting Alliance, University of Colorado Denver School of Public Affairs, MPC, Darigold, R, Milk protein concentrate, Professional, Milk, Food industry, Pleasure, South Dakota State University, Coronavirus Scientific Advisory Board (Turkey), MPI, MPP, Candy, MIC, Development, Growth, Union of Sales and Marketing Professionals, Doctor of Philosophy, Permeation, University, Management, Research, Nestlé

Before coming to Idaho Milk Products, he attended South Dakota State University pursuing his Ph.D. in dairy manufacturing under the supervision of Dr. Lloyd Metzger, a member of our Scientific Advisory Board.

Key Points: 
  • Before coming to Idaho Milk Products, he attended South Dakota State University pursuing his Ph.D. in dairy manufacturing under the supervision of Dr. Lloyd Metzger, a member of our Scientific Advisory Board.
  • “Venkat joined Idaho Milk Products at a momentous time for the development of our MIC (Milk Innovation Center) and has already made a significant contribution in bringing us to where we are today,” said Daragh Maccabee, CEO of Idaho Milk Products.
  • “I am delighted with Kevin’s decision to join our team,” commented Daragh Maccabee, CEO of Idaho Milk Products.
  • The production of MPC (Milk Protein Concentrate), MPI (Milk Protein Isolate) and MPP (Milk Permeate Powder) is at a level that meets the spec needs of global customers, and the effort to continue thriving on sustainability at farm and factory put Idaho Milk Products ahead of the curve.”
    Idaho Milk Products proudly supports personal, professional, educational, technical and above all, leadership development to help employees realize their potential and be part of a world-class team.

Senior Leadership Changes at Idaho Milk Products

Retrieved on: 
Tuesday, January 24, 2023
Common white wave, Marketing, Global Accounting Alliance, University of Colorado Denver School of Public Affairs, MPC, Darigold, R, Milk protein concentrate, Professional, Milk, Food industry, Pleasure, South Dakota State University, Coronavirus Scientific Advisory Board (Turkey), MPI, MPP, Candy, MIC, Development, Growth, Union of Sales and Marketing Professionals, Doctor of Philosophy, Permeation, University, Management, Research, Nestlé

Before coming to Idaho Milk Products, he attended South Dakota State University pursuing his Ph.D. in dairy manufacturing under the supervision of Dr. Lloyd Metzger, a member of our Scientific Advisory Board.

Key Points: 
  • Before coming to Idaho Milk Products, he attended South Dakota State University pursuing his Ph.D. in dairy manufacturing under the supervision of Dr. Lloyd Metzger, a member of our Scientific Advisory Board.
  • “Venkat joined Idaho Milk Products at a momentous time for the development of our MIC (Milk Innovation Center) and has already made a significant contribution in bringing us to where we are today,” said Daragh Maccabee, CEO of Idaho Milk Products.
  • “I am delighted with Kevin’s decision to join our team,” commented Daragh Maccabee, CEO of Idaho Milk Products.
  • The production of MPC (Milk Protein Concentrate), MPI (Milk Protein Isolate) and MPP (Milk Permeate Powder) is at a level that meets the spec needs of global customers, and the effort to continue thriving on sustainability at farm and factory put Idaho Milk Products ahead of the curve.”
    Idaho Milk Products proudly supports personal, professional, educational, technical and above all, leadership development to help employees realize their potential and be part of a world-class team.

Aprea Therapeutics to Participate in 6th Annual DNA Damage and Response (DDR) Inhibitors Summit

Retrieved on: 
Thursday, January 19, 2023
Coronavirus Scientific Advisory Board (Turkey), Therapy, Doctor of Philosophy, DNA, Clinic, Biomarker, DDR, APRE, Toxicity, Pharmaceutical industry

DOYLESTOWN, Pa., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced that it will participate in the 6th Annual DDR Inhibitors Summit, held in Boston, Massachusetts from January 24 – January 26, 2023.

Key Points: 
  • DOYLESTOWN, Pa., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced that it will participate in the 6th Annual DDR Inhibitors Summit, held in Boston, Massachusetts from January 24 – January 26, 2023.
  • Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea, will participate in a panel discussion entitled “How Are Newer Targets Being Validated to Move Towards Clinical Trials?” and present in two sessions.
  • In addition, Eric Brown, Ph.D., Scientific Consultant to Aprea and a member of the Scientific Advisory Board, will present on Repli-Biom, Aprea’s proprietary discovery platform of novel synthetic lethal targets and biomarkers.
  • Details for the panel and presentations are as follows:
    Panel Discussion: How are Newer Targets Being Validated to Move Towards Clinical Trials?

ABIONYX Pharma Reports Positive Results from Phase 2a Pilot Clinical Trial Evaluating CER-001 in the Treatment of Septic Patients at High Risk of Developing Acute Kidney Injury

Retrieved on: 
Monday, January 16, 2023
COVID-19, Research, Infectious Diseases, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Other Science, Disease, Coronavirus Scientific Advisory Board (Turkey), Gambat Liver Transplant Unit, Dialysis, University, AKI, Septic, Safety, Lancet, Death, Nephrology, Patient, Sepsis, Acute kidney injury, Frontiers in Medicine, Pharmaceutical industry, Medicine

Loreto Gesualdo, full Professor, Head of the Nephrology, Dialysis and Transplantation Unit, University of Bari Aldo Moro, Italy, and lead investigator of the RACERS study stated: “We are incredibly excited to share results from this pilot Phase 2a trial evaluating CER-001 in septic patients at high risk of developing acute kidney injury.

Key Points: 
  • Loreto Gesualdo, full Professor, Head of the Nephrology, Dialysis and Transplantation Unit, University of Bari Aldo Moro, Italy, and lead investigator of the RACERS study stated: “We are incredibly excited to share results from this pilot Phase 2a trial evaluating CER-001 in septic patients at high risk of developing acute kidney injury.
  • There is a complete lack of treatment options for septic patients at high risk of developing acute kidney injury, a disease that in 2019 had an estimated 13.7 million related deaths globally (Lancet 2022; 400: 2221–48).
  • The trial shows promising positive results across a variety of primary and secondary endpoints.
  • The potential use of CER-001 in septic patients is currently under clinical development.

Simulations Plus Releases DILIsym X (DSX) Beta with Redesigned Software Infrastructure

Retrieved on: 
Thursday, January 12, 2023
Research, Technology, Health Technology, Professional Services, Software, Biometrics, Biotechnology, Pharmaceutical, Health, Science, Coronavirus Scientific Advisory Board (Turkey), DSS, Hepatotoxicity, Pharma, Simulations Plus, FDA, Risk, Drug development, Partnership, Patient, Software, SLP, DSX, QST, Medical device

Simulations Plus , Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that its DILIsym Services (DSS) division has released DILIsym® version X (DSX) Beta, the latest version of its flagship quantitative systems toxicology (QST) software for predicting and investigating drug-induced liver injury (DILI).

Key Points: 
  • Simulations Plus , Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that its DILIsym Services (DSS) division has released DILIsym® version X (DSX) Beta, the latest version of its flagship quantitative systems toxicology (QST) software for predicting and investigating drug-induced liver injury (DILI).
  • DSX represents a great advance in that it simplifies the use of the software and greatly increases the speed with which it provides results.
  • This will enable much wider adoption of the software by Pharma, regulators, and academics.”
    Dr. Brett Howell , president of the DILIsym Services division, added: “DILIsym is increasingly being used for high impact applications in the safety space.
  • For the past 12 years, the DILIsym Services division has coordinated the DILI-sim Initiative, which is a public-private partnership that has guided development of the DILIsym software package.

Veru Announces Appointment of Dr. David D. Ho as Chairman of its Infectious Disease Scientific Advisory Board

Retrieved on: 
Tuesday, January 10, 2023
Diamond, Disease, SAB, HIV/AIDS, Columbia University Irving Medical Center, National Academy of Medicine, COVID-19, Infection, National Center for Advancing Translational Sciences, HIV, Severe acute respiratory syndrome coronavirus 2, Aaron Diamond AIDS Research Center, Columbia University, National academy, Patient, Clyde, American Academy, The arts, Research, Antibody, Harvard Medical School, TIME, Physician, Coronavirus Scientific Advisory Board (Turkey), Vaccine, Pharmaceutical industry, Medicine, Science

FL, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced the appointment of David D. Ho, M.D., a trailblazer of infectious disease viral research and therapeutic development, as Chairman of its Scientific Advisory Board (SAB).

Key Points: 
  • FL, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced the appointment of David D. Ho, M.D., a trailblazer of infectious disease viral research and therapeutic development, as Chairman of its Scientific Advisory Board (SAB).
  • “Today’s appointment of Dr. Ho as Chairman of Veru’s SAB illustrates our commitment to building a team of scientific experts to support our goal of developing and delivering life-saving therapies to patients with COVID-19 and other viral ARDS-related diseases,” said Mitchell Steiner, M.D., Chairman, President, and Chief Executive Officer of Veru.
  • In his noteworthy research, Dr. Ho discovered the nature of HIV replication, and the resulting innovative combination therapy remarkably enabled patients to manage this disease.
  • In addition, Dr. Ho is leading a multi-disciplinary team of physicians, scientists, and engineers to advance the development of new drugs that target SARS-CoV-2 mutants.

Biotech Industry Leaders Join Deep Genomics Board of Directors and Scientific Advisory Board

Retrieved on: 
Friday, January 6, 2023
Health, Technology, Genetics, Artificial Intelligence, Pharmaceutical, Biotechnology, Ness, Sarepta, IPO, Organic acid, GlaxoSmithKline, Coronavirus Scientific Advisory Board (Turkey), RNA, CSO, Lead, Oncology, Oligonucleotide, Intellia Therapeutics, Art, FRSC, Drug discovery, Doctor of Philosophy, Therapy, Drug development, Pfizer, Molecular biology, Ionis Pharmaceuticals, SoftBank Group, IP Group, Investment, CFO, Sarepta Therapeutics, GSK, Genomics, Sirna Therapeutics, Patient, AstraZeneca, Biology, Atlas, Khosla Ventures, AI, DPU, Regeneron Pharmaceuticals, Moderna, Atlas Venture, PTC, Regulus Therapeutics, University, PTC Therapeutics, Pharmaceutical industry

and Mark Edbrooke, Ph.D. have joined the Scientific Advisory Board.

Key Points: 
  • and Mark Edbrooke, Ph.D. have joined the Scientific Advisory Board.
  • “These industry leaders will lend valuable support and advice to Deep Genomics as we advance our revolutionary AI drug discovery platform toward the goal of bringing programmable RNA medicines to patients,” said Brendan Frey, Ph.D., FRSC, Founder and CEO of Deep Genomics.
  • Chip has more than 20 years of experience leading innovative biotech companies and also serves as a Director of Axcella Health.
  • He is a serial biotech entrepreneur and investor, most notably having founded Intellia Therapeutics, Korro Bio and Liberate Bio.

ImmunoGen Appoints Michael Vasconcelles, MD, as Executive Vice President, Research, Development, and Medical Affairs

Retrieved on: 
Wednesday, January 4, 2023
Biotechnology, Health, Science, Research, Oncology, Dana–Farber Cancer Institute, Cancer, ImmunoGen, Frazier Healthcare Partners, Harvard Medical School, Executive Committee, Health, Oncology, Head, Therapy, Medicine, MD, Sanofi, Knowledge, SRL Diagnostics, Yissum Research Development Company of the Hebrew University, Flatiron, Rest, Personalized medicine, Partner, Growth, Patient, Hospital, Medical Affairs Bureau, Acquisition, ADC, High society, Coronavirus Scientific Advisory Board (Turkey), IMGN, Senior advisor, Brigham and Women's Hospital, Control, Transplant, Pharmaceutical industry, Genzyme, Research, Northwestern University

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Michael Vasconcelles, MD, has been appointed Executive Vice President, Research, Development, and Medical Affairs.

Key Points: 
  • ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Michael Vasconcelles, MD, has been appointed Executive Vice President, Research, Development, and Medical Affairs.
  • "I am delighted to welcome Mike to our Executive Committee to lead the next stage of growth for these activities.
  • Mike brings over 30 years of experience in the discovery, global development, and approval of transformative cancer therapies.
  • He also spent several years at Takeda/Millennium, where he was Senior Vice President and Head of the Oncology Therapy Area Unit.

HeartBeam Issues Shareholder Letter and Provides Corporate Update

Retrieved on: 
Thursday, December 29, 2022
Wearables, Mobile Technology, Technology, Medical Devices, FDA, Cardiology, Software, Biotechnology, Biometrics, Health, IPO, Standard of care, SAB, Infarction, IP, 3D, MD, Research, Death, Multimedia, Version 1, Coronary artery disease, Arrhythmia, Patient, ECG, Mortality, Emergency department, Letter, Coronavirus Scientific Advisory Board (Turkey), Physician, Intellectual property, FDA, Patent, MIT EAD Airframe Version 2, Doctor of Philosophy, Chest pain, Management, Pharmaceutical industry, Medical imaging, Medical device

View the full release here: https://www.businesswire.com/news/home/20221229005042/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20221229005042/en/
    2022 was a transformative year for HeartBeam and for our technology and business, highlighted by ongoing advancements in our product launch timeline for the HeartBeam AIMIGo™ 12-Lead 3D Vector Electrocardiogram (ECG) Device and HeartBeam AIMI™.
  • Developed by our pioneering team, our HeartBeam AIMI and HeartBeam AIMIGo solutions will transform the way patients and doctors detect heart attacks.
  • We expect the HeartBeam AIMI system for use in acute care settings to receive regulatory approval in the near future.
  • He continues to lead the overall technology strategy and development of the HeartBeam AIMI and HeartBeam AIMIGo platforms.